Join
Live feed
·
PRReleasevia Quantisnow
PolyPid Ltd. logo

PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

ByQuantisnow·Wall Street's wire, on your screen.
PYPD· PolyPid Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PYPD (PolyPid Ltd.) and more on Quantisnow.